850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies

Ruth Plummer; Mikael Sodergren; Brid Ryan; Ilian Tachkov; Vikash Reebye; Tim Meyer; David Pinato; Debashis Sarker; Bristi Basu; Sarah Blagden; Natalie Cook; Jeff Evans; Jeffrey Yachnin; Cheng-Ean Chee; Daneng Li; Anthony El-Khoueiry; Maria Diab; Kai-Wen Huang; Antonio D'Alessio; Claudia Fulgenzi; Marcus Noel; Bridget Keenan; Devalingam Mahalingam; Nina Raulf; Rose Hogson; Choon Ping Tan; Joanna Nicholls; Alison Adderkin; Julia Vassiliadou; Robert Habib; John Rossi; Nagy Habib

doi:10.1136/jitc-2022-SITC2022.0850

Article info

Regular and Young Investigator Award Abstracts

Combination Immunotherapies

850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies

Free

Authors

Ruth Plummer Newcastle University, Newcastle-upon-Tyne, UK PubMed articles Google scholar articles
Mikael Sodergren Imperial College London, London, UK PubMed articles Google scholar articles
Brid Ryan MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Ilian Tachkov MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Vikash Reebye MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Tim Meyer University College London, London, UK PubMed articles Google scholar articles
David Pinato Imperial College London, London, UK PubMed articles Google scholar articles
Debashis Sarker Kings College London, London, UK PubMed articles Google scholar articles
Bristi Basu University of Cambridge, Cambridge, UK PubMed articles Google scholar articles
Sarah Blagden Univeristy of Oxford, Oxford, UK PubMed articles Google scholar articles
Natalie Cook The Christie NHS Foundation Trust, Manchester, UK PubMed articles Google scholar articles
Jeff Evans University of Glasgow, Glasgow, UK PubMed articles Google scholar articles
Jeffrey Yachnin Karolinska University Hospital, Stockholm, Sweden PubMed articles Google scholar articles
Cheng-Ean Chee National University Cancer Institute, Singapore, Singapore PubMed articles Google scholar articles
Daneng Li City of Hope Comprehensive Cancer Center, Duarte, CA, United States PubMed articles Google scholar articles
Anthony El-Khoueiry University of Southern California, Los Angeles, CA, United States PubMed articles Google scholar articles
Maria Diab Emory University, Atlanta, GA, United States PubMed articles Google scholar articles
Kai-Wen Huang National Taiwan University Hospital, Taipei, Taiwan PubMed articles Google scholar articles
Antonio D'Alessio Imperial College London, London, UK PubMed articles Google scholar articles
Claudia Fulgenzi Imperial College London, London, UK PubMed articles Google scholar articles
Marcus Noel Medstar Georgetown University Hospital, Washington, WA, United States PubMed articles Google scholar articles
Bridget Keenan University of California San Francisco, San Francisco, CA, United States PubMed articles Google scholar articles
Devalingam Mahalingam Northwestern University, Chicago, IL, United States PubMed articles Google scholar articles
Nina Raulf MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Rose Hogson MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Choon Ping Tan MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Joanna Nicholls Imperial College London, London, UK PubMed articles Google scholar articles
Alison Adderkin MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Julia Vassiliadou MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
Robert Habib MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles
John Rossi Beckman Research Institute, City of Hope, CA, United States PubMed articles Google scholar articles
Nagy Habib MiNA Therapeutics Ltd, London, UK PubMed articles Google scholar articles

Citation

Plummer R, Sodergren M, Ryan B, et al

850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0850

Publication history

First published December 8, 2022.

Online issue publication

April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password